On April 26, Beqvez (fidanacogene elaparvovec-dzkt) won approval to treat some adults with moderate-to-severe hemophilia B. The drugmaker set the list price at $3.5 million, a company spokesperson told CNBC. Another hemophilia B gene medication, Hemgenix, costs the same.
In a phase 3 study of 45 patients, researchers found a decrease in annualized bleeding rates among those who received the medication, which was well-tolerated.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
